Uniqure N.v Intrinsic Value Calculation – Credit Suisse Boosts uniQure’s Price Target to $55 for 2023, Maintains Outperform Rating
March 19, 2023
Trending News ☀️
UNIQURE ($NASDAQ:QURE): Credit Suisse has recently released a report that boosts uniQure’s price target to $55 for 2023, a marked increase from the previous $51. The analysts at Credit Suisse have maintained their Outperform rating on the stock, citing the company’s strong outlook and potential for growth in the coming years. uniQure is a life sciences company that focuses on gene therapy products. The company works with a wide range of partners and collaborators, including academic institutions, biotechnology companies, and pharmaceutical companies. It has recently gained traction in the gene therapy space, developing treatments for rare diseases like hemophilia, Parkinson’s disease, and Huntington’s disease. The increased price target set by Credit Suisse is reflective of uniQure’s consistent progress and strong partnerships with leading industry players.
In addition, the company has been able to maintain a healthy balance sheet and to strategically allocate resources towards research and development of new products. Furthermore, the continued positive outcomes from clinical trials of its gene therapy treatments have helped to solidify the company’s position as a leader in the gene therapy space. Overall, Credit Suisse’s increased price target and Outperform rating of uniQure illustrates the strong market sentiment towards the company and its potential for long-term growth. With its robust pipeline, strategic partnerships, and promising clinical data, uniQure is well-positioned to capitalize on the growing demand for gene therapy treatments and drive value for its shareholders over the long term.
Price History
On Friday, UNIQURE N.V stock opened at $19.4 and closed at $19.3, down by 2.1% from prior closing price of 19.8. This positive news has seen UNIQURE N.V overall media coverage remain mostly positive with many analysts showing optimism for the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
| Total Revenues | Net Income | Net Margin |
| 106.48 | -126.79 | -143.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
| Operations | Investing | Financing |
| -145.06 | -182.73 | 1.45 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 704.96 | 228.96 | 10.13 |
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 144.5% | – | -109.5% |
| FCF Margin | ROE | ROA |
| -152.8% | -16.2% | -10.3% |
Analysis – Uniqure N.v Intrinsic Value Calculation
GoodWhale has conducted an analysis of UNIQURE N.V‘s wellbeing. According to our proprietary Valuation Line, we estimate UNIQURE N.V’s intrinsic value to be around $41.5 per share. Currently, the stock is trading at $19.3, making it undervalued by 53.5%. We believe this presents an attractive opportunity for investors looking to add UNIQURE N.V to their portfolio. More…
Peers
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
Summary
UNIQURE N.V. is an innovative gene therapy company focused on developing potentially curative therapies for people suffering from genetic and other serious diseases. Its robust pipeline of gene therapy candidates is designed to target both rare and common diseases, with potential for wide-ranging therapeutic benefit. Recent investment analysis of the company has been positive, with Credit Suisse boosting its price target to $55 for 2023 and maintaining an Outperform rating.
The company has seen a steady increase in investor interest, and its share price has been steadily rising as a result. With a promising pipeline of therapies and growing investor confidence, UNIQURE N.V. is set up for long-term success.
